Calico Life Sciences LLC
12
3
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Role: collaborator
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
Role: collaborator
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Role: lead
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
Role: collaborator
An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
Role: lead
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
Role: collaborator
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
Role: collaborator
Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration
Role: lead
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
Role: lead
A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262
Role: lead
Expanded Access to ABBV-CLS-484
Role: lead
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
Role: lead
All 12 trials loaded